Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial)Berm, E. J. J., Hak, E., Postma, M., Boshuisen, M., Breuning, L., Brouwers, J. R. B. J., Dhondt, T., Jansen, P. A. F., Kok, R. M., Maring, J. G., van Marum, R., Mulder, H., Oude Voshaar, R., Risselada, A. J., Venema, H., Vleugel, L. & Wilffert, B., 31-Jan-2015, In : TRIALS. 16, 1, 7 p., 37.
Research output: Contribution to journal › Article › Academic › peer-review
- Pharmacotherapy and Pharmaceutical Care
- Pharmacoepidemiology and Pharmacoeconomics
- Microbes in Health and Disease (MHD)
- Methods in Medicines evaluation & Outcomes research (M2O)
- Interdisciplinary Centre Psychopathology and Emotion regulation (ICPE)
- Reproductive Origins of Adult Health and Disease (ROAHD)
- Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET)
- Value, Affordability and Sustainability (VALUE)
Background: Nortriptyline and venlafaxine are commonly used antidepressants for treatment of depression in older patients. Both drugs are metabolized by the polymorphic cytochrome P450-2D6 (CYP2D6) enzyme and guidelines for dose adaptations based on the CYP2D6 genotype have been developed. The CYP2D6 Screening Among Elderly (CYSCE) trial is designed to address the potential health and economic value of genotyping for CYP2D6 in optimizing dose-finding of nortriptyline and venlafaxine.
Methods/Design: In a pragmatic randomized controlled trial, patients diagnosed with a major depressive disorder according to the DSM-IV and aged 60 years or older will be recruited from psychiatric centers across the Netherlands. After CYP2D6 genotyping determined in peripheral blood obtained by finger-prick, patients will be grouped into poor, intermediate, extensive, or ultrarapid metabolizers. Patients with deviant genotype (that is poor, intermediate or ultrarapid genotype) will be randomly allocated to an intervention group in which the genotype and dosing advice is communicated to the treating physician, or to a control group in which patients receive care as usual. Additionally, an external reference group of patients with the extensive metabolizer genotype is included. Primary outcome in all groups is time needed to obtain an adequate blood level of the antidepressant drug. Secondary outcomes include adverse drug reactions measured by a shortened Antidepressant Side-Effects Checklist (ASEC), and cost-effectiveness of the screening.
Discussion: Results of this trial will guide policy-making with regard to pharmacogenetic screening prior to treatment with nortriptyline or venlafaxine among older patients with depression.
|Number of pages||7|
|Publication status||Published - 31-Jan-2015|
- CYP2D6, Pharmacogenetics, Depression, Nortriptyline, Venlafaxine, LC-MS/MS, ANTIDEPRESSANTS, PSYCHIATRY, DEPRESSION, GUIDELINES, LIFE, DISEASE, ENZYMES, BURDEN, UPDATE